Sign in Subscribe
Pharmaceutical industry

American Biogenetic Sciences Appoints Former Eli Lilly Executive as President and CEO

Strategic Insights

— 1 min read

American Biogenetic Sciences, a biotechnology company researching and developing diagnostic tests and treatments for various conditions, has appointed John S. North, a seasoned executive with nearly three decades of experience at Eli Lilly and Company, as its new President and CEO. North will lead the company's efforts to enhance market penetration for its FDA-cleared diagnostic products and negotiate licensing agreements with large pharmaceutical companies for its neuroscience drug candidates.

Key Takeaways:

  • John S. North, a former Eli Lilly executive, has been appointed as the new President and CEO of American Biogenetic Sciences, bringing with him nearly three decades of experience in international sales and marketing.
  • North will focus on enhancing market penetration for ABS' FDA-cleared diagnostic products and negotiating licensing agreements with large pharmaceutical companies for its neuroscience drug candidates.
  • North has served in various key positions at Eli Lilly, including Director of International Government and Public Affairs, Director of New Product Planning for Europe, and Director of Marketing for the Dista Products division in the United Kingdom.
  • He was responsible for opening new markets for Lilly products, overcoming obstacles to market penetration, and acting as lead negotiator for Lilly in striking collaborative agreements with foreign governments and organizations.
  • Previous President, Stephen Ip, Ph.D., will step down but remain as a consultant to the company.
  • ABS researches and develops diagnostic tests for cardiac conditions and infectious diseases, as well as new treatments for neurological conditions including epilepsy, migraine, mania, Parkinson's, and Alzheimer's disease.

Statistics:

  • 30 years: The amount of time John S. North spent at Eli Lilly and Company.
  • 1986: The year Prozac was launched in Europe under North's leadership as Director of New Product Planning.
  • 20: The number of countries ABS' Global Scientific Network operates in, including the US, Europe, Israel, Russia, and China.
  • 50: The age of John S. North at the time of his appointment as President and CEO of ABS.
  • 1998: The year Stephen Ip, Ph.D., started serving as President, Chief Operating Officer, and a member of the Board of Directors of ABS.

Sources:

  • American Biogenetic Sciences press release, "Former Eli Lilly Executive Brings International Sales and Marketing Expertise to ABS" (Nov. 17, 1998).
  • Eli Lilly and Company press releases and corporate reports cited throughout the article.

Read more